Supplementary Table 1. Perfusion imaging criteria for patients in the late window

	DAWN	DEFUSE-3
Core definition	MRI: ADC <620 x 10 ⁻³ mm ² /sec CTP: relative CBF <30%	MRI: ADC <620 x 10 ⁻³ mm ² /sec CTP: relative CBF <30%
Penumbra definition	NA	Tmax >6 sec
lschemic core volume	Age >80: ≤20 mL Age <80 & NIHSS 10-20: ≤30 mL Age <80 & NIHSS >20: ≤50 mL	≤70 mL
Mismatch volume	NA	≥15 mL
Mismatch ratio penumbra/core	NA	≥1.8

DAWN, DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo; DE-FUSE-3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; MRI, magnetic resonance imaging; ADC, apparent diffusion coefficient; CTP, computed tomography perfusion; CBF, cerebral blood flow; NIHSS, National Institutes of Health Stroke Scale; DWI, diffusion-weighted imaging.

Supplementary Table 2. Multivariable analysis for the selected outcomes for late window patients with and without advance imaging

	aOR (95% CI)	Р
mRS 0-2 at 90 days (n=260)	1.40 (0.74–2.64)*	0.296
Parenchymal hemorrhage type 2 (PH2) (n=267)	1.68 (0.42–6.76) [†]	0.466
Petechial hemorrhage (n=267)	0.98 (0.47–2.02) [*]	0.950
Good mTICI (2b-3) (n=233)	1.62 (0.65–4.05) [§]	0.305
Mortality at 90 days (n=212)	1.07 (0.44–2.57) [∥]	0.885

OR, odds ratio; Cl, confidence interval; mRS, modified Rankin Scale; mTICl, modified Thrombolysis in Cerebral Infarction; CAD, coronary artery disease; NIHSS, National Institutes of Health Stroke Scale; IV-tPA, intravenous tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage; ICA, internal carotid artery; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; DTAS, direct to angiosuite strategy.

^{*}Age, sex, CAD, initial NIHSS, IV-tPA, mTICl 2b-3, sICH, ICA treatment timing, ICA stenting, and ASPECTS; [†]Diabetes mellitus, atrial fibrillation, DTAS strategy, antiplatelet regimen, first pass effect, and ASPECTS; [†]Ethnicity, atrial fibrillation, ASPECTS, sICH, and ICA stenting; [§]Age, sex, CAD, initial NIHSS, IV-tPA, mTICl 2b-3, sICH, ICA treatment timing, and ASPECTS; [§]Sex, CAD, smoking, initial NIHSS, IV-tPA, intracranial artery occlusion location, and ICA stenting.